



New generation technologies
in regenerative therapies.



CONTACT US

✉ amniosbiotech@gmail.com

☎ +54 9 1140399339

Heart Failure Is a **Leading Cause** **of Morbimortality Worldwide**

64.3 M



Patients worldwide

50%



Die within five years of diagnosis

70%



Caused by ischemic events



Current Treatments **Are Not Enough**



Pharmacological therapy



Bypass surgery



Angioplasty



Heart transplant

None of these therapies **reverse or repair the damaged heart muscle.**

An **Injectable Biomimetic Hydrogel** Inspired by Acellular Human Birth Tissue

It could **prevent or reverse heart failure**



Restoring cardiac function



Improving quality of life



Reducing rehospitalization and mortality rates





Our Therapy Addresses **Key Mechanisms** of Tissue Repair

Angiogenesis


Proliferation

Anti-fibrosis

Anti-inflammation



Hydrogel



Control




Ovine acute myocardial infarction model - **28 days after treatment** (n = 5 per group).

We Are Creating Value Based On Our Technology



Patentability study confirms our technology is novel and protectable.

A Large Market with a Defined Clinical Entry Point




Our Product is Superior to Others Cardiac Regenerative Therapies

FEATURES	AMNOVA	verve RENOVA MYOKARDIA		
		CELL THERAPY	GENE THERAPY	BIOMATERIAL
Cell-free	✓	✗	✓	✓
Rich in multiple regenerative molecules	✓ ✓	✓	✗	✓
Does not cause rejection	✓	✗	✓	SOME
Offers sustained release	✓	✓	✓	✓
Esterile and re-administrable	✓	✗	✗	✓
Lower in production costs	✓	✗	✗	✗
Does not contain animal derivatives	✓	✓	✓	SOME

REGENERATIVE MOLECULES

+20 year´s experience
Preclinical and clinical
research in cardiac
regeneration.



BIRTH TISSUE HYDROGEL

In vitro and in vivo studies
demonstrated cardiac
regenerative effects



RECOMBINANT HYDROGEL

Develop a biomimetic
recombinant composition

PRECLINICAL STUDIES

Preclinical MI studies
conducted under FDA-
compliant conditions.

CLINICAL TRIALS

Phase I- in patients
undergoing bypass
surgery.

2025

NOW

2027

2028

2029

BIRTH TISSUE

+10 year´s experience Clinical
research and applications in
wound healing regeneration.
+2k patients treated.



INTELLECTUAL
PROPERTY

EXPANSION OF
APPLICATIONS

Invest in the Future of Heart Regeneration

📅 OPEN UNTIL JUNE 2026

USD 150K

⏏ Active Round

Looking for
matching ticket:
USD 150k



USD 150k
committed investor

📅 MARCH 2027

USD 250K-500k

⏏ Next Round

Looking for
co-investor:
USD 250k-500k



USD 500k
Lead investor
committed



Interested investors can reach out for further details.



B2B

Technology Association



Licensing



Revenue from upfront fees



Royalties



Milestones



CO- FOUNDERS



Pilar Ferrer CEO

Biologist and PhD student.



Mariano Berra CTO

Pharmacist.



Daniela Olea CSO

Biotechnologist and CONICET Researcher.



**Alejandro Berra
SCIENTIFIC ADVISOR**

Biochemist and CONICET Researcher.

ADVISORY BOARD



**Alberto
Crottogini**
R&D Advisor



Mariano Belaich
Biotech industry
Advisor

CORE TEAM



**María del Rosario
Bauzá**
Scientific Manager

FOLLOW OUR
JOURNEY



✉ amniosbiotech@gmail.com

☎ +54 9 1140399339

THANK YOU

FOR YOUR ATTENTION

